Switch to:
More From Other Websites
BioTime's AST-OPC1 Cleared by FDA for Phase I/IIa Study Aug 28 2014
BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure Aug 28 2014
BioTime to Collaborate With the University of Wisconsin and Louvain University in Test of... Aug 28 2014
BioTime Subsidiary Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a... Aug 27 2014
BIOTIME INC Files SEC form 8-K, Other Events Aug 27 2014
Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of... Aug 27 2014
Asterias Biotherapeutics Announces Investor Briefing Conference Call and Webcast Aug 25 2014
Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A... Aug 21 2014
BIOTIME INC Financials Aug 19 2014
BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure Aug 12 2014
BioTime Receives FDA Premarket Notification Clearance for Premvia™ 510(k) Aug 12 2014
BioTime Announces Second Quarter 2014 Results and Recent Developments Aug 12 2014
BIOTIME INC Files SEC form 10-Q, Quarterly Report Aug 11 2014
BIOTIME INC Files SEC form 8-K, Other Events Jul 31 2014
BioTime, Inc. Subsidiary OncoCyte Corporation Expands Clinical Development of Bladder Cancer... Jul 31 2014
Asterias Biotherapeutics Announces Live Investor Webcast Jul 24 2014
BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure Jul 14 2014
BioTime Announces Issuance of 14 Patents in the Fields of Regenerative Medicine, and Cancer... Jul 14 2014
BioTime Announces Issuance of 14 Patents in the Fields of Regenerative Medicine, and Cancer... Jul 14 2014
BIOTIME INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements... Jul 07 2014


Add Notes, Comments or Ask Questions

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK